Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2277 • ACR Convergence 2024
Switching to a Targeted Drug with a Different Mode of Action After Discontinuation of the First TNF Inhibitor Is Associated with Better Drug Survival Compared to a Second TNF Inhibitor in Rheumatoid Arthritis: A Propensity Score-matched Analysis from the Czech ATTRA Registry
Herman Mann¹, Jana Baranová², Pavel Horak³, Karel Pavelka⁴, Ladislav Šenolt⁵, Jiří Vencovský⁵, Kateřina Kusalová² and Jakub Závada⁴, and ATTRA registry, ¹Revmatologický ústav, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: TNF inhibitors (TNFi) are currently the most commonly used first-line targeted therapy for patients with rheumatoid arthritis (RA). After discontinuation of the first TNFi,…
Abstract Number: 2540 • ACR Convergence 2024
Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis
Mary Huang, Richard Bell, Toolika Singh and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation due to cellular infiltration and inflammatory mediators. Type I interferons (IFN) have…
Abstract Number: 2656 • ACR Convergence 2024
Short-Term Effectiveness of a Walk with Ease Program Delivered by Telephone on Arthritis-Related Symptoms, Function, and Physical Activity
Christine Pellegrini, Sara Wilcox, Yesil Kim, Katherine Devivo, Scott Jamieson, Kailyn Horn and Daniel Heidtke, University of South Carolina, Columbia, SC
Background/Purpose: Walk With Ease (WWE) is a 6-week arthritis-appropriate evidence-based physical activity program traditionally offered in a face-to-face format. However, as many populations encounter participation…
Abstract Number: 0040 • ACR Convergence 2024
Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Gary Sims¹, Mia Collins², Natalie Pursell³, Teneema Kuriakose¹, Fanyi Jiang⁴, Kristi Moore⁵, Lucie Bertrand⁵, Melissa Lasaro⁵, Jessica Neisen⁶, Scott Manetz⁷, Gabriel Wong⁸, Patrick Riley⁵, Iain McInnes⁹, Kyriakos Konstantinidis¹⁰ and David Close⁸, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Dicerna, Lexington, ⁴Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁵Alexion, AstraZeneca Rare Disease, New Haven, CT, ⁶Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹⁰Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
Abstract Number: 0057 • ACR Convergence 2024
Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages
Hideto Takada¹, Brian Hattel², Marie Feser³, LauraKay Moss², Yuko Okamoto⁴, Mark Gillespie⁵, Adam Savage⁵, Troy Torgerson⁶, V. Michael Holers⁷, Kevin Deane⁸ and Kristen Demoruelle⁹, ¹Tokyo Women's Medical University, Denver, CO, ²University of Colorado Anschutz Medical Campus, Denver, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Tokyo Women's Medical University Division of Rheumatology, Shinjyuku-ku, Tokyo, Japan, ⁵Allen Institute for Immunology, Seattle, WA, ⁶Allen Institute for Immunology, Enumclaw, WA, ⁷University of Colorado, Denver, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Serum elevations of ACPA in the absence of inflammatory arthritis is a well-established risk factor for the future development of clinical RA. The lung…
Abstract Number: 0140 • ACR Convergence 2024
Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas
Fabiola Atzeni¹, Fabio Cacciapaglia², Elena Bartoloni Bocci³, Matteo Piga⁴, Garifallia Sakellariou⁵, Ombretta Viapiana⁶, Alessandro Giollo⁷, SIMONE PARISI⁸, Maria Sole Chimenti⁹, Ennio Giulio Favalli¹⁰, Addolorata Corrado¹¹, Eleonora Celletti¹², Ivan Giovannini¹³, Serena Guiducci¹⁴, Elisa Gremese¹⁵, Andreina Manfredi¹⁶, Francesca Romana Spinelli¹⁷ and Gian Luca Erre¹⁸, and "Cardiovascular Obesity and Rheumatic DISeaases" Study Group of the Italian Society of Rheumatology, ¹University of Messina, Italy, Messina, Italy, ²Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ³Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁴Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁵Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁶Rheumatology Unit, University of Verona, Verona, Italy, ⁷Azienda Ospedale Università Padova, Padova, Padua, Italy, ⁸Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ¹⁰ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹¹Rheumatology Unit, University of Foggia, Foggia, Italy, ¹²Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴University of Florence, Pistoia, Italy, ¹⁵Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁶University of Modena and Reggio Emilia, Modena, ¹⁷Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁸Rheumatology Unit - University of Sassari, Sassari, Italy
Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…
Abstract Number: 0222 • ACR Convergence 2024
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ummugulsum Gazel¹, Ozun Bayindir Tsechelidis³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth¹ and Sibel Aydin⁶, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: There are discrepancies between physical examination and Ultrasound (US) in detecting inflammation in Rheumatoid Arthritis (RA). In this study, we aimed to understand, according…
Abstract Number: 0364 • ACR Convergence 2024
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Insa Mannstadt¹, J. Alex B. Gibbons² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…
Abstract Number: 0461 • ACR Convergence 2024
Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis
ivan Ferraz-Amaro¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴ and Miguel Angel Gonzalez-Gay⁵, ¹Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain
Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…
Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Hari Prasanna¹, Charles Inderjeeth², Johannes Nossent³ and KHALID ALMUTAIRI⁴, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ⁴The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
Abstract Number: 0495 • ACR Convergence 2024
Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Manuel Ugarte-Gil², Risto Perich³, Cesar Pastor⁴, Graciela Alarcon⁵ and RV, Gamboa-Cardenas⁶, ¹Hncase, Arequipa, Peru, ²Universidad Cientifica del Sur, Lima, Lima, Peru, ³Hospital Almenara, Lima, Peru, ⁴UNMSM, LIMA, Peru, ⁵The University of Alabama at Birmingham, Oakland, CA, ⁶Universidad Científica del Sur, Lima, Lima, Peru
Background/Purpose: The triglyceride/glucose index (TGI) is a metabolic marker associated with insulin resistance and cardiovascular risk. In patients with Rheumatoid Arthritis (RA), chronic inflammation and…
Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Josef Smolen¹, Ted Mikuls², James Galloway³, Ulf Müller-Ladner⁴, Jeffrey Curtis⁵, Motomu Hashimoto⁶, Tsutomu Takeuchi⁷, Ernest Choy⁸, Yoshiya Tanaka⁹, Carlos Cara¹⁰, Bernard Lauwerys¹¹, Nicola Tilt¹², Baran Ufuktepe¹³ and Peter C. Taylor¹⁴, ¹Medical University of Vienna, Vienna, Austria, ²University of Nebraska Medical Center, Omaha, NE, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴Justus-Liebig University Giessen, Bad Nauheim, Germany, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶Osaka Metropolitan University, Osaka, Japan, ⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁸Cardiff University School of Medicine, Cardiff, United Kingdom, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰UCB Pharma, Madrid, Spain, ¹¹UCB Pharma, Brussels, Belgium, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Istanbul, Turkey, ¹⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
Abstract Number: 0800 • ACR Convergence 2024
Associations of Rheumatoid Arthritis Polygenic Risk with Age at Onset, Serostatus, and Interstitial Lung Disease
Gregory McDermott¹, Pierre-Antoine Juge², Keigo Hayashi³, Xiaosong Wang⁴, Misti Paudel⁵, Sung Hae Chang⁶, Qianru Zhang⁷, Vanessa Kronzer⁸, Kevin Mueller⁹, Alene Saavedra⁹, Katarina Bade⁹, Grace Qian⁴, Emily Kowalski⁹, Kathleen Vanni⁴, Jing Cui⁹ and Jeffrey Sparks¹⁰, ¹Brigham and Women's Hospital, Brookline, MA, ²Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ³Brigham and Women’s Hospital, Brookline, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁶Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁷Harard Medical School, Cambridge, ⁸Mayo Clinic, Rochester, MN, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Recent rheumatoid arthritis (RA) genome-wide association studies (GWAS) identified 196 risk loci. Polygenic risk scores (PRS) use GWAS summary statistics to aggregate genome-wide genetic…
Abstract Number: 0893 • ACR Convergence 2024
Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response
Ismael Sánchez Pareja¹, Carlos Perez-Sanchez¹, Dani Toro-Domínguez², Laura Muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño³, Rafaela Ortega-Castro⁴, Jerusalem Calvo Gutierrez⁵, María Lourdes Ladehesa-Pineda⁶, Concepción Aranda-Valera³, María Carmen Ábalos-Aguilera⁷, Christian Merlo-Ruiz⁷, Mª Angeles Aguirre-Zamorano⁸, Nuria Barbarroja¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera⁶, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Fundación Progreso y Salud, Andalusian Government, Granada, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁴Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁵HU Reina Sofia, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: Characterize the molecular landscape of RA patients using a multi-omic approach encompassing transcriptomics and proteomics and assess its association with disease stage and therapeutic…

« Previous Page
1
…
4
5
6
7
8
…
188
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].